Kiora Stock Analysis

KPRX
 Stock
  

USD 3.71  0.02  0.54%   

The big decline in price over the last few months for Kiora Pharmaceuticalsmay raise some interest from investors. The stock closed today at a share price of 3.71 on 137,800 in trading volume. The company management teams failed to add value to investors and position the firm supply of money to exploit market volatility in October. However, diversifying your holdings with Kiora Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.83. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kiora Pharmaceuticals partners.
Please see Correlation Analysis.
  
The Kiora Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Kiora Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kiora Stock analysis module also helps to analyze the Kiora Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Kiora Stock Analysis Notes

About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Kiora Pharmaceuticals was now reported as 1.38. The company recorded a loss per share of 1.44. Kiora Pharmaceuticals had not issued any dividends in recent years. The entity had 40.00 - 1.00 split on the 27th of September 2022. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Kiora Pharmaceuticals contact the company at 781 788 8869 or learn more at https://www.kiorapharma.com.

Kiora Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kiora Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kiora Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kiora Pharmaceuticals generated a negative expected return over the last 90 days
Kiora Pharmaceuticals has high historical volatility and very poor performance
Kiora Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 12.06 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (5.14 M).
Kiora Pharmaceuticals currently holds about 2.43 M in cash with (10.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64.
Roughly 12.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 - Marketscreener.com

Kiora Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Kiora Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kiora Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Kiora Largest EPS Surprises

Earnings surprises can significantly impact Kiora Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-08-06
2020-06-30-0.43-0.380.0511 
2016-03-29
2015-12-31-0.19-0.24-0.0526 
2016-05-13
2016-03-31-0.25-0.31-0.0624 
View All Earnings Estimates

Kiora Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kiora Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kiora Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kiora Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
25th of August 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
5th of August 2022
Unclassified Corporate Event
View
4th of August 2022
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
1st of August 2022
Unclassified Corporate Event
View
28th of July 2022
Unclassified Corporate Event
View
26th of July 2022
Financial Statements and Exhibits. Other Events. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Entry into a Material Definitive Agreement
View
21st of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
31st of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View

Kiora Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Kiora Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiora Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Xtx Topco LtdCommon Shares13.9 K31 K
Wells Fargo CompanyCommon Shares85.00.0
Wells Fargo CompanyCommon Shares78.00.0
Wells Fargo CompanyCommon Shares78.00.0
Wells Fargo CompanyCommon Shares77.00.0
Wells Fargo CompanyCommon Shares40.00.0
Wells Fargo CompanyCommon Shares36.00.0
Note, although Kiora Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kiora Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 46.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kiora Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Kiora Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (36.27) % which means that it has lost $36.27 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (158.02) %, meaning that it created substantial loss on money invested by shareholders. Kiora Pharmaceuticals management efficiency ratios could be used to measure how well kiora pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of November, Kiora Pharmaceuticals secures the Risk Adjusted Performance of 0.0417, mean deviation of 8.19, and Downside Deviation of 9.58. Kiora Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Kiora Pharmaceuticals, which can be compared to its peers in the industry. Please verify Kiora Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Kiora Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 3.71 per share. Given that Kiora Pharmaceuticals has jensen alpha of 0.5464, we recommend you to check Kiora Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.

Kiora Pharmaceuticals Price Movement Analysis

The output start index for this execution was fourty-eight with a total number of output elements of thirteen. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Kiora Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Kiora Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiora Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiora Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiora Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kiora Pharmaceuticals Predictive Daily Indicators

Kiora Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kiora Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kiora Pharmaceuticals Forecast Models

Kiora Pharmaceuticals time-series forecasting models is one of many Kiora Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kiora Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Kiora Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kiora Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kiora shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Kiora Pharmaceuticals. By using and applying Kiora Stock analysis, traders can create a robust methodology for identifying Kiora entry and exit points for their positions.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Current Kiora Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kiora analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kiora analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.0Strong Buy2Odds
Kiora Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kiora analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kiora stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kiora Pharmaceuticals, talking to its executives and customers, or listening to Kiora conference calls.
Kiora Analyst Advice Details

Kiora Stock Analysis Indicators

Kiora Pharmaceuticals stock analysis indicators help investors evaluate how Kiora Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kiora Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kiora Pharmaceuticals stock analysis, traders can identify Kiora Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio1.04
Fifty Two Week Low3.2110
Shares Short Prior Month147.5k
Average Daily Volume Last 10 Day485.94k
Average Daily Volume In Three Month697.24k
Shares Percent Shares Out8.91%
Short Percent Of Float8.93%
Forward Price Earnings-0.28
Float Shares652.37k
Fifty Two Week High71.6000
Enterprise Value To Ebitda-0.36
Fifty Day Average6.7920
Two Hundred Day Average14.5430
Please see Correlation Analysis. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for analysis

When running Kiora Pharmaceuticals price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 M
Return On Assets
(0.29) 
Return On Equity
(1.24) 
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Kiora Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.